Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

24.16
-0.3500-1.43%
Pre-market: 24.380.2200+0.91%04:01 EDT
Volume:7.44M
Turnover:185.66M
Market Cap:1.68B
PE:-5.98
High:26.68
Open:25.07
Low:24.01
Close:24.51
52wk High:71.50
52wk Low:8.73
Shares:69.37M
Float Shares:57.53M
Volume Ratio:0.97
T/O Rate:12.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0399
EPS(LYR):-3.4602
ROE:-157.61%
ROA:-15.72%
PB:5.17
PE(LYR):-6.98

Loading ...

Barclays Sticks to Their Buy Rating for uniQure (QURE)

TIPRANKS
·
Yesterday

uniQure weakness creates attractive opportunity, says Wells Fargo

TIPRANKS
·
Yesterday

RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’

TIPRANKS
·
Yesterday

Top Midday Decliners

MT Newswires Live
·
Yesterday

uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright

TIPRANKS
·
Yesterday

France's MaaT Pharma H1 Operating Loss Widens on Higher R&D Costs

Reuters
·
Yesterday

uniQure falls -38.4%

TIPRANKS
·
Yesterday

Crude Oil Down 1%; US Job Openings Fall In August

Benzinga Earnings
·
Yesterday

U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle

Reuters
·
Sep 29

Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings

Benzinga Earnings
·
Sep 29

Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday

MT Newswires Live
·
Sep 29

UniQure Stock Drops After Huntington's Drug Results Disappoint at 4-Year Mark

Dow Jones
·
Sep 29

UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble

MT Newswires Live
·
Sep 29

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

GlobeNewswire
·
Sep 29

Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)

TIPRANKS
·
Sep 03

uniQure submits biologics license application to FDA for ifezuntirgene inilparvo

TIPRANKS
·
Sep 02

Uniqure N.v. : William Blair Resumes Coverage with Outperform Rating

THOMSON REUTERS
·
Sep 02

uniQure Seeks FDA Priority Review for Huntington’s Gene Therapy AMT-130 BLA

Reuters
·
Sep 02

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

GlobeNewswire
·
Sep 02

uniQure resumed with an Outperform at William Blair

TIPRANKS
·
Sep 02